SIREN : 822117305
PHARMAPE is a French company founded 9 years ago, specialized in the sector Gestion de fonds. Based in VER-LES-CHARTRES (28630), this company of category PME shows in 2020 a net income positive of 8 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-18
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|
| Revenue | N/C | N/C | N/C | N/C |
| Net income | 8 367 € | 8 685 € | 9 439 € | 7 844 € |
| EBITDA | -677 € | -342 € | 413 € | -1 200 € |
| Net margin | N/C | N/C | N/C | N/C |
In 2020, PHARMAPE generates positive net income of 8 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2020: 8 k€ -> 8 k€.
-677 €
-677 €
8 367 €
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 99%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.0 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability.
0.009%
99.223%
0.002
In 2020, the debt ratio of PHARMAPE (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2020, the financial autonomy of PHARMAPE (99.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2020, the repayment capacity of PHARMAPE (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 670 days. Excellent situation: suppliers finance 670 days of the operating cycle (retail model).
0 €
0 j
670 j
0 j
Based on 54 transactions of similar company sales
in 2020,
the value of PHARMAPE is estimated at
63 131 €
(range 24 476€ - 115 976€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARMAPE with other companies in the same sector:
The revenue of PHARMAPE is not publicly disclosed (confidential accounts filed with INPI).
Yes, PHARMAPE generated a net profit of 8 k€ in 2020.
The headquarters of PHARMAPE is located in VER-LES-CHARTRES (28630), in the department Eure-et-Loir.
The tax return of PHARMAPE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARMAPE operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.